Availability by country, dated, with primary sources posts 61–82

post #60 is right about the mechanism and I think understates the practical bit.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

Worth separating two things that post #58 runs together.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

post #64 answers the question as asked. The question underneath it is different.

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Coming back to post #66, because the follow-up matters more than the original answer.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

Coming back to post #69, because the follow-up matters more than the original answer.

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

Picking up post #69: that is the part I would want checked first.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.